Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of diphenhydramine hydrochloride in preparation of medicine for treating experimental autoimmune encephalomyelitis

A diphenhydramine hydrochloride, autoimmune technology, applied in the field of medicine, can solve the problems of incomplete cure of MS, poor prognosis of multiple sclerosis, etc., and achieve the effect of inhibiting the incidence of inflammation

Active Publication Date: 2017-10-27
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] The prognosis of multiple sclerosis is poor. Drugs approved by the FDA, such as mitoxantrone and dimethyl fumarate, can only delay and alleviate the severity of the onset but cannot completely cure MS. Therefore, it is urgent to develop new drugs through new ways. Drug to better ease disease woes for MS patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of diphenhydramine hydrochloride in preparation of medicine for treating experimental autoimmune encephalomyelitis
  • Application of diphenhydramine hydrochloride in preparation of medicine for treating experimental autoimmune encephalomyelitis
  • Application of diphenhydramine hydrochloride in preparation of medicine for treating experimental autoimmune encephalomyelitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1: the effect of diphenhydramine hydrochloride in experimental autoimmune encephalomyelitis (EAE)

[0036] Materials and methods

[0037] 1. Experimental animals

[0038] C57BL / 6J mice (female, 8-12 weeks old) were purchased from Nanjing Institute of Biomedicine and Shanghai Slack Experimental Animal Co., Ltd. All animal experiments were approved by the Animal Ethics Committee of the Second Military Medical University.

[0039] 2. EAE modeling and in vivo diphenhydramine hydrochloride intervention

[0040] 1) Preparation of complete Freund's adjuvant: Dissolve tuberculin Mtb (purchased from Difco, USA) in incomplete Freund's adjuvant CFA (purchased from sigma), add CFA while grinding with a ceramic mortar, and finally dissolve The concentration is 4mg / ml;

[0041] 2) MOG 35-55 powder (myelin oligodendrocyte glycoprotein 35-55 , purchased from Jill Biochemical Company) was dissolved in sterile PBS, and the final dissolved concentration was 2mg / ml;

[00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medicine. The invention uses more than 600 kinds of FDA-approved small molecule drugs to carry out high-throughput screening, and finds that diphenhydramine hydrochloride has the most obvious inhibitory effect on CD4+ T cells. The present invention has further constructed experimental autoimmune encephalomyelitis animal model (EAE model), and adopts EAE model to study the effect of diphenhydramine hydrochloride on inflammatory demyelinating injury in vivo, and experiment finds that diphenhydramine hydrochloride has Regulate TH17 cell differentiation and inflammatory demyelinating injury in vivo. The invention provides the application of diphenhydramine hydrochloride in the preparation of drugs for preventing or treating experimental autoimmune encephalomyelitis, and in the preparation of drugs for preventing or treating multiple sclerosis.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a new medical application of diphenhydramine hydrochloride, that is, the application of diphenhydramine hydrochloride in the preparation of drugs for preventing or treating experimental autoimmune encephalomyelitis and multiple sclerosis. Background technique [0002] Diphenhydramine Hydrochloride (Diphenhydramine Hydrochloride) is an antiallergic non-prescription medicine, and its chemical structural formula is as shown in formula (I), molecular formula: C 17 h 22 Molecular weight of NOCl: 291.82, melting point 168-172°C. [0003] [0004] CAS number: 147-24-0 [0005] MDL number: MFCD00012479 [0006] EINECS No.: 205-687-2 [0007] RTECS No.: KR7000000 [0008] PubChem number: 24277771 [0009] Diphenhydramine hydrochloride is currently clinically used for skin allergies, such as urticaria, eczema, dermatitis, drug eruption, itching, neurodermatitis, insect bites, sol...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/135A61P37/02A61P25/00
Inventor 何成曹莉赵明
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com